Skip to main content
SpringerLink
Log in

Vascular Permeability/Vascular Endothelial Growth Factor

  • Chapter
Angiogenesis

The vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) family has more than seven members including VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, PlGF, and Trimeresurus flavoviridis (T. f.) svVEGFs. Except for VEGF-E and T.f. svVEGFs, all members are encoded in the mammalian genome and involved in angiogenesis and/or lymphangiogenesis. Among these five gene products, VEGF-A (also known as VEGF and VPF) binds two receptor-type tyrosine kinases, VEGFR1 and VEGFR2, and transduces major signals for angiogenesis and vascular permeability. VEGF-A expression is efficiently induced by hypoxia, and regulates not only physiological but also most of the pathological angiogenesis, such as tumor angiogenesis. Since VEGF-A utilizes VEGFR2 as a direct stimulator for angiogenesis, this VEGF-VEGFR2 system represents an ideal pharmaceutical target for suppressing various diseases. Interestingly, VEGFR1 has also been shown to be deeply involved in various pathological processes in cancer as well as inflammatory diseases via a mechanism different from VEGFR2, suggesting that VEGF-VEGFR1 is another attractive target for suppressing human diseases. VEGF-C/D and their receptor VEGFR3 play a central role in lymphangiogenesis, and the blocking of this system significantly decreases lymph node metastasis in animal models of cancer. VEGF-E, a VEGFR2- specific ligand, induces angiogenesis with fewer side effects such as edema and inflammatory responses which are commonly observed on treatment with VEGF-A. Thus, VEGF-E is a useful candidate for proangiogenic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Risau W. Mechanism of angiogenesis. Nature 1997; 386:671–4.

    Article  PubMed  CAS  Google Scholar 

  2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182–6.

    PubMed  CAS  Google Scholar 

  3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27–31.

    Article  PubMed  CAS  Google Scholar 

  4. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219:983–5.

    Article  PubMed  CAS  Google Scholar 

  5. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin -binding growth factor specific for vascular endothelial cells. Biochem Bophys Res Commun1989; 161:851–8.

    Article  CAS  Google Scholar 

  6. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246:1309–12.

    Article  PubMed  CAS  Google Scholar 

  7. Leung DW, Cachianes G, Kuang W-J, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1898; 246:1306–9.

    Article  Google Scholar 

  8. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Rev 1997; 18:4–25.

    Article  CAS  Google Scholar 

  9. Shibuya M. Role of VEGF-Flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 1995; 67:281–316.

    Article  PubMed  CAS  Google Scholar 

  10. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE 2001; RE21.

    Google Scholar 

  11. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006; 312:549–60.

    Article  PubMed  CAS  Google Scholar 

  12. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841–4.

    Article  PubMed  CAS  Google Scholar 

  13. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353–64.

    Article  PubMed  CAS  Google Scholar 

  14. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2:795–803.

    Article  PubMed  CAS  Google Scholar 

  15. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–42.

    Article  PubMed  CAS  Google Scholar 

  16. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15:290–8.

    PubMed  CAS  Google Scholar 

  17. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002; 1:219–27.

    Article  PubMed  CAS  Google Scholar 

  18. Veikkola T, Jussila L, Makinen T, et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 2001; 20:1223–31.

    Article  PubMed  CAS  Google Scholar 

  19. Karkkainen MJ, Haiko P, Sainio K, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004; 5:74–80.

    Article  PubMed  CAS  Google Scholar 

  20. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nature Med 2001; 7:186–91.

    Article  PubMed  CAS  Google Scholar 

  21. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368–80.

    Article  PubMed  CAS  Google Scholar 

  22. Lyttle DJ, Fraser KM, Fleming SB, et al. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol 1994; 68:84–92.

    PubMed  CAS  Google Scholar 

  23. Ogawa S, Oku A, Sawano A, et al. A novel type of Vascular Endothelial Growth Factor: VEGF-E (NZ-7 VEGF) preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 1998; 273:31273–82.

    Article  PubMed  CAS  Google Scholar 

  24. Meyer M, Clauss M, Lepple-Wienhues A, et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 1999; 18:363–74.

    Article  PubMed  CAS  Google Scholar 

  25. Wise LM, Veikkola T, Mercer AA, et al. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc Natl Acad Sci USA 1999; 96:3071–6.

    Article  PubMed  CAS  Google Scholar 

  26. Junqueira de Azevedo IL, Farsky SH, Oliveira ML, et al. Molecular cloning and expression of a functional snake venom vascular endothelium growth factor (VEGF) from the Bothrops insularis pit viper. A new member of the VEGF family of proteins. J Biol Chem 2001; 276:39836–42.

    Article  PubMed  CAS  Google Scholar 

  27. Komori Y, Nikai T, Taniguchi K, et al. Vascular endothelial growth factor VEGF-like heparin-binding protein from the venom of Vipera aspis aspis (Aspic viper). Biochemistry 1999; 38:11796–803.

    Article  PubMed  CAS  Google Scholar 

  28. Gasmi A, Bourcier C, Aloui Z, et al. Complete structure of an increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom. ICPP is angiogenic via vascular endothelial growth factor receptor signalling. J Biol Chem 2002; 277:29992–8.

    Article  PubMed  CAS  Google Scholar 

  29. Takahashi H, Hattori S, Iwamatsu A, et al. A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential xignaling via VEGF receptor-1. J Biol Chem 2004; 279:46304–14.

    Article  PubMed  CAS  Google Scholar 

  30. Yamazaki Y, Takani K, Atoda H, et al. Snake venom vascular endothelial growth factors (VEGFs) exhibit potent activity through their specific recognition of KDR (VEGF receptor 2). J Biol Chem 2003; 278:51985–8.

    Article  PubMed  CAS  Google Scholar 

  31. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407:242–8.

    Article  PubMed  CAS  Google Scholar 

  32. Funakoshi H, Nakamura T. Hepatocyte growth factor: from diagnosis to clinical applications. Clin Chim Acta 2003; 327:1–23.

    Article  PubMed  CAS  Google Scholar 

  33. LeCouter J, Moritz DR, Li B, et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003; 299:890–3.

    Article  PubMed  CAS  Google Scholar 

  34. Pepper MS, Wasi S, Ferrara N, et al. In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells. Exp Cell Res 1994; 210:298–305.

    Article  PubMed  CAS  Google Scholar 

  35. Hirakawa S, Kodama S, Kunstfeld R, et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005; 201:1089–99.

    Article  PubMed  CAS  Google Scholar 

  36. Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Natute Neurosci 2005; 8:85–92.

    Article  CAS  Google Scholar 

  37. Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004; 429:413–7.

    Article  PubMed  CAS  Google Scholar 

  38. Le Bras B, Barallobre MJ, Homman-Ludiye J, et al. VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain. Nature Neurosci 2006; 9:340–8.

    Article  PubMed  CAS  Google Scholar 

  39. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380:435–9.

    Article  PubMed  CAS  Google Scholar 

  40. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380:439–42.

    Article  PubMed  CAS  Google Scholar 

  41. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005; 109:227–41.

    Article  CAS  Google Scholar 

  42. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79:1283–316.

    PubMed  CAS  Google Scholar 

  43. Soker S, Fidder H, Neufeld G, et al. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 1996; 271:5761–7.

    Article  PubMed  CAS  Google Scholar 

  44. Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92:735–45.

    Article  PubMed  CAS  Google Scholar 

  45. Maes C, Carmeliet P, Moermans K, et al. Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev 2002; 111:61–73.

    Article  PubMed  CAS  Google Scholar 

  46. Carmeliet P, Ng YS, Nuyens D, et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nature Med 1999; 5:495–502.

    Article  PubMed  CAS  Google Scholar 

  47. Ruhrberg C, Gerhardt H, Golding M, et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002; 16:2684–98.

    Article  PubMed  CAS  Google Scholar 

  48. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-t in fibroblastic and epithelial cells. J Biol Chem 1994; 269:6271–4.

    PubMed  CAS  Google Scholar 

  49. Warren RS, Yuan H, Matli MR, et al. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 1996; 271:29483–8.

    Article  PubMed  CAS  Google Scholar 

  50. Ferrara N, Chen H, Davis-Smyth T, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Med 1998; 4:336–40.

    Article  PubMed  CAS  Google Scholar 

  51. Safran M, Kaelin WG Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003; 111:779–83.

    PubMed  CAS  Google Scholar 

  52. Dor Y, Porat R, Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 2001; 280:C1367–74.

    PubMed  CAS  Google Scholar 

  53. Liu Y, Cox SR, Morita T, et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 1995; 77:638–43.

    PubMed  CAS  Google Scholar 

  54. Ema M, Taya S, Yokotani N, et al. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997; 94:4273–8.

    Article  PubMed  CAS  Google Scholar 

  55. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271–5.

    Article  PubMed  CAS  Google Scholar 

  56. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292:464–8.

    Article  PubMed  CAS  Google Scholar 

  57. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Med 2003; 9:677–84.

    Article  PubMed  CAS  Google Scholar 

  58. Ferrara N, Houck K, Jakeman L, et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13(1):18–32.

    PubMed  CAS  Google Scholar 

  59. Volm M, Koomagi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997; 74:64–8.

    Article  PubMed  CAS  Google Scholar 

  60. Yoshiji H, Gomez DE, Shibuya M, et al. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 1996; 56:2013–6.

    PubMed  CAS  Google Scholar 

  61. Fava RA, Olsen NJ, Spencer-Green G, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994; Jul 1 180(1):341–6.

    Article  PubMed  CAS  Google Scholar 

  62. Dong J, Grunstein J, Tejada M, et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 2004; 23:2800–10.

    Article  PubMed  CAS  Google Scholar 

  63. Liang WC, Wu X, Peale FV, et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006; 281:951–61.

    Article  PubMed  CAS  Google Scholar 

  64. Asano M, Yukita A, Matsumoto T, et al. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res 1995; 55:5296–301.

    PubMed  CAS  Google Scholar 

  65. Kong HL, Hecht D, Song W, et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 1998; 9:823–33.

    Article  PubMed  CAS  Google Scholar 

  66. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99:11393–8.

    Article  PubMed  CAS  Google Scholar 

  67. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 2000; 60:970–5.

    PubMed  CAS  Google Scholar 

  68. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60:2178–89.

    PubMed  CAS  Google Scholar 

  69. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542–50.

    Article  PubMed  CAS  Google Scholar 

  70. Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007;12:713–8.

    Article  PubMed  CAS  Google Scholar 

  71. Luo JC, Yamaguchi S, Shinkai A, et al. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites yumors. Cancer Res 1998; 58:2652–60.

    PubMed  CAS  Google Scholar 

  72. Luo J-C, Toyoda M, Shibuya M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an anti-vascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 1998; 58:2594–2600.

    PubMed  CAS  Google Scholar 

  73. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Med 2002; 8:831–40.

    PubMed  CAS  Google Scholar 

  74. De Bandt M, Ben Mahdi MH, Ollivier V, et al. Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J Immunol 2003; 171:4853–9.

    PubMed  CAS  Google Scholar 

  75. Murakami M, Iwai S, Hiratsuka S, et al. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocyte/ macrophages. Blood 2006; 108:1849–56.

    Article  PubMed  CAS  Google Scholar 

  76. Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991; 88:9267–71.

    Article  PubMed  CAS  Google Scholar 

  77. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Med 2001; 7:575–83.

    Article  PubMed  CAS  Google Scholar 

  78. Aase K, von Euler G, Li X, et al. Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation 2001; 104:358–64.

    PubMed  CAS  Google Scholar 

  79. Karkkainen MJ, Ferrell RE, Lawrence EC, et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nature Genet 2000; 25:153–9.

    Article  PubMed  CAS  Google Scholar 

  80. Kiba A, Sagara H, Hara T, et al. VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice. Biochem Biophys Res Commun 2003; 301:371–7.

    Article  PubMed  CAS  Google Scholar 

  81. Zheng Y, Murakami M, Takahashi H, et al. Chimeric VEGF-ENZ7/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation. Arterioscler Thromb Vasc Biol 2006; 26:2019–26.

    Article  PubMed  CAS  Google Scholar 

  82. Larcher F, Murillas R, Bolontrade M, et al. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 1998; 17:303–11.

    Article  PubMed  CAS  Google Scholar 

  83. Detmar M, Brown LF, Schon MP, et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998; 111:1–6.

    Article  PubMed  CAS  Google Scholar 

  84. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990; 5:519–24.

    PubMed  CAS  Google Scholar 

  85. De Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255:989–91.

    Article  PubMed  CAS  Google Scholar 

  86. Terman BI, Carrion ME, Kovacs E, et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 199; 6:1677–83.

    Google Scholar 

  87. Matthews W, Jordan CT, Gavin M, et al. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci USA 1991; 88:9026–30.

    Article  PubMed  CAS  Google Scholar 

  88. Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72:835–46.

    Article  PubMed  CAS  Google Scholar 

  89. Galland F, Karamysheva A, Pebusque MJ, et al. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene 1993; 8:1233–40.

    PubMed  CAS  Google Scholar 

  90. Covassin LD, Villefranc JA, Kacergis MC, et al. Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish. Proc Natl Acad Sci USA 2006; 103:6554–9.

    Article  PubMed  CAS  Google Scholar 

  91. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Flt1, two receptors for Vascular Endothelial Growth Factor. J Biol Chem 1994; 269:26988–95.

    PubMed  CAS  Google Scholar 

  92. Seetharam L, Gotoh N, Maru Y, et al. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995; 10:135–47.

    PubMed  CAS  Google Scholar 

  93. Sawano A, Takahashi T, Yamaguchi S, et al. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for Placenta Growth Factor (PlGF), which is related to vascular endothelial growth factor (VEGF). Cell Growth Differ 1996; 7:213–21.

    PubMed  CAS  Google Scholar 

  94. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90:10705–9.

    Article  PubMed  CAS  Google Scholar 

  95. Yamaguchi S, Iwata K, Shibuya M. Soluble Flt-1 (soluble VEGFR-1), a potent natural anti-angiogenic molecule in mammals, is phylogenetically conserved in avians. Biochem Biophys Res Commun 2002; 291:554–9.

    Article  PubMed  CAS  Google Scholar 

  96. Fong GH, Rossant J, Gertsentein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376:66–70.

    Article  PubMed  CAS  Google Scholar 

  97. Hiratsuka S, Minowa O, Kuno J, et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998; 95:9349–54.

    Article  PubMed  CAS  Google Scholar 

  98. Clauss M, Weich H, Breier G, et al. The vascular endothelial growth factor receptor Flt-1 madiates biological activities. J Biol Chem 1996; 271:17629–34.

    Article  PubMed  CAS  Google Scholar 

  99. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelilal growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87:3336–43.

    PubMed  CAS  Google Scholar 

  100. Sawano A, Iwai S, Sakurai Y, et al. Vascular endothelial growth factor receptor-1 (Flt-1) is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001; 97:785–91.

    Article  PubMed  CAS  Google Scholar 

  101. Hiratsuka S, Maru Y, Okada A, et al. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001; 61:1207–13.

    PubMed  CAS  Google Scholar 

  102. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med 2001; 7:1194–201.

    Article  PubMed  CAS  Google Scholar 

  103. Hiratsuka S, Nakamura K, Iwai S, et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung specific metastasis. Cancer Cell 2002; 2:289–300.

    Article  PubMed  CAS  Google Scholar 

  104. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438:820–7.

    Article  PubMed  CAS  Google Scholar 

  105. Zhao Q, Egashira K, Hiasa KI, et al. Essential role of vascular endothelial growth factor and Flt-1 signals in neointimal formation after periadventitial injury. Arterioscler Thromb Vasc Biol 2004; 24:2284–9.

    Article  PubMed  CAS  Google Scholar 

  106. Ohtani K, Egashira K, Hiasa KI, et al. Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells. Circulation 2004; 110:2444–52.

    Article  PubMed  CAS  Google Scholar 

  107. Koga K, Osuga Y, Yoshino O, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88:2348–51.

    Article  PubMed  CAS  Google Scholar 

  108. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649–58.

    PubMed  CAS  Google Scholar 

  109. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672–83.

    Article  PubMed  CAS  Google Scholar 

  110. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006; 443:993–7.

    Article  PubMed  CAS  Google Scholar 

  111. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376:62–6.

    Article  PubMed  CAS  Google Scholar 

  112. Takahashi T, Yamaguchi S, Chida K, et al. A Single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells. EMBO J 2001; 20:2768–78.

    Article  PubMed  CAS  Google Scholar 

  113. Zeng H, Sanyal S, Mukhopadhyay D. Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem 2001; 276:32714–9.

    Article  PubMed  CAS  Google Scholar 

  114. Takahashi T, Ueno H, Shibuya M. VEGF activates Protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999; 18:2221–30.

    Article  PubMed  CAS  Google Scholar 

  115. Matsumoto T, Bohman S, Dixelius J, et al. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J 2005; 24:2342–53.

    Article  PubMed  CAS  Google Scholar 

  116. Sakurai Y, Ohgimoto K, Kataoka Y, et al. Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci USA 2005; 102:1076–81.

    Article  PubMed  CAS  Google Scholar 

  117. Carmeliet P, Lampugnani MG, Moons L, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999; 98:147–157.

    Article  PubMed  CAS  Google Scholar 

  118. Shay-Salit A, Shushy M, Wolfovitz E, et al. VEGF receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells. Proc Natl Acad Sci USA 2002; 99: 9462–7.

    Article  PubMed  CAS  Google Scholar 

  119. Stupack, DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol 2004; 64:207–38.

    Article  PubMed  CAS  Google Scholar 

  120. Fukumura D, Gohongi T, Kadambi A, et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 2001; 98:2604–9.

    Article  PubMed  CAS  Google Scholar 

  121. van Spronsen DJ, De Mulder PH. Targeted approaches for treating advanced clear cell renal carcinoma. Onkologie 2006; 29:394–402.

    Article  PubMed  Google Scholar 

  122. Nakamura K, Taguchi E, Miura T, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 2006; 66:9134–42.

    Article  PubMed  CAS  Google Scholar 

  123. Dumont DJ, Jussila L, Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998; 282:946–9.

    Article  PubMed  CAS  Google Scholar 

  124. Morisada T, Oike Y, Yamada Y, et al. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood 2005; 105:4649–56.

    Article  PubMed  CAS  Google Scholar 

  125. Kawasaki T, Kitsukawa T, Bekku Y, et al. A requirement for neuropilin-1 in embryonic vessel formation. Development 1999; 126:4895–902.

    PubMed  CAS  Google Scholar 

  126. Yuan L, Moyon D, Pardanaud L, et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 2002; 129:4797–806.

    PubMed  CAS  Google Scholar 

  127. Hiratsuka S, Watanabe A, Aburatani H, et al. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nature Cell Biol 2006; 8:1369–75.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Oncology, Tokyo Medical and Dental University, 113-8519, Tokyo, Japan

    Masabumi Shibuya

Authors
  1. Masabumi Shibuya
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

    William D. Figg

  2. Department of Surgery Harvard Medical School and Vascular Biology Program, Children's Hospital Boston, Boston, MA, USA

    Judah Folkman

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Shibuya, M. (2008). Vascular Permeability/Vascular Endothelial Growth Factor. In: Figg, W.D., Folkman, J. (eds) Angiogenesis. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-71518-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-71518-6_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-71517-9

  • Online ISBN: 978-0-387-71518-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation